Suppr超能文献

细胞外基质金属蛋白酶诱导因子(CD147)由C/EBPβ诱导产生,在间变性淋巴瘤激酶阳性(ALK+)和间变性淋巴瘤激酶阴性(ALK-)的间变性大细胞淋巴瘤中表达存在差异。

EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

作者信息

Schmidt Janine, Bonzheim Irina, Steinhilber Julia, Montes-Mojarro Ivonne A, Ortiz-Hidalgo Carlos, Klapper Wolfram, Fend Falko, Quintanilla-Martínez Leticia

机构信息

Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany.

Departamento de Patología, Centro Médico ABC (The American British Cowdray Medical Center), Mexico City, Mexico.

出版信息

Lab Invest. 2017 Sep;97(9):1095-1102. doi: 10.1038/labinvest.2017.54. Epub 2017 Jun 5.

Abstract

Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is characterized by expression of oncogenic ALK fusion proteins due to the translocation t(2;5)(p23;q35) or variants. Although genotypically a T-cell lymphoma, ALK+ ALCL cells frequently show loss of T-cell-specific surface antigens and expression of monocytic markers. C/EBPβ, a transcription factor constitutively overexpressed in ALK+ ALCL cells, has been shown to play an important role in the activation and differentiation of macrophages and is furthermore capable of transdifferentiating B-cell and T-cell progenitors to macrophages in vitro. To analyze the role of C/EBPβ for the unusual phenotype of ALK+ ALCL cells, C/EBPβ was knocked down by RNA interference in two ALK+ ALCL cell lines, and surface antigen expression profiles of these cell lines were generated using a Human Cell Surface Marker Screening Panel (BD Biosciences). Interesting candidate antigens were further analyzed by immunohistochemistry in primary ALCL ALK+ and ALK- cases. Antigen expression profiling revealed marked changes in the expression of the activation markers CD25, CD30, CD98, CD147, and CD227 after C/EBPβ knockdown. Immunohistochemical analysis confirmed a strong, membranous CD147 (EMMPRIN) expression in ALK+ ALCL cases. In contrast, ALK- ALCL cases showed a weaker CD147 expression. CD274 or PD-L1, an immune inhibitory receptor ligand, was downregulated after C/EBPβ knockdown. PD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPβ in ALK+ ALCL in generating an immunosuppressive environment. Finally, no expression changes of T-cell or monocytic markers were detected. In conclusion, surface antigen expression profiling demonstrates that C/EBPβ plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets. The multiple roles of CD147 in migration, adhesion, and invasion, as well as T-cell activation and proliferation suggest its involvement in the pathogenesis of ALCL.

摘要

间变性淋巴瘤激酶阳性(ALK+)间变性大细胞淋巴瘤(ALCL)的特征是由于t(2;5)(p23;q35)易位或变异导致致癌性ALK融合蛋白的表达。尽管在基因层面上是T细胞淋巴瘤,但ALK+ ALCL细胞经常表现出T细胞特异性表面抗原的缺失和单核细胞标志物的表达。C/EBPβ是一种在ALK+ ALCL细胞中持续过度表达的转录因子,已被证明在巨噬细胞的激活和分化中起重要作用,并且在体外能够将B细胞和T细胞祖细胞转分化为巨噬细胞。为了分析C/EBPβ在ALK+ ALCL细胞异常表型中的作用,通过RNA干扰在两个ALK+ ALCL细胞系中敲低C/EBPβ,并使用人类细胞表面标志物筛选面板(BD生物科学公司)生成这些细胞系的表面抗原表达谱。通过免疫组织化学在原发性ALK+和ALK- ALCL病例中进一步分析有趣的候选抗原。抗原表达谱显示C/EBPβ敲低后激活标志物CD25、CD30、CD98、CD147和CD227的表达有明显变化。免疫组织化学分析证实ALK+ ALCL病例中CD147(细胞外基质金属蛋白酶诱导因子)有强烈的膜表达。相比之下,ALK- ALCL病例中CD147表达较弱。免疫抑制受体配体CD274或PD-L1在C/EBPβ敲低后下调。与ALK- ALCL相比,PD-L1在ALK+ ALCL中也表现出更强的表达,表明C/EBPβ在ALK+ ALCL中产生免疫抑制环境方面有额外作用。最后,未检测到T细胞或单核细胞标志物的表达变化。总之,表面抗原表达谱表明C/EBPβ在ALK+ ALCL细胞的激活状态中起关键作用,并揭示CD147和PD-L1是重要的下游靶点。CD147在迁移、黏附和侵袭以及T细胞激活和增殖中的多种作用表明其参与了ALCL的发病机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验